Abstract 455P
Background
Nutritional status and proper dietary intake have a vital role in cancer prognosis and progression. Alterations in metabolic system due to chemotherapy and cancer can lead to high prevalence of malnutrition. It can be attributable to cancer, therapy effect and decreased food intake. Malnutrition has negative impact on patients treatment, side effects, immunity, Quality of life (QOL) and prolonged hospital stay and expense. Our study aims to assess the nutritional status, timely intervention and QOL in cancer patients undergoing chemotherapy.
Methods
A prospective hospital-based multidisciplinary interventional study was conducted in 97 patients with known histological malignancies who had received chemotherapy as inpatients in oncology wards at Ramaiah hospital in Bangalore for a period of six months. Detailed interview of patients and their care-takers were analysed in structured formats. Malnutrition and QOL were assessed using PG-SGA scale and EORTC QLQ C-30 questionnaire respectively. QOL was assessed at the beginning and at the end of the chemotherapy whereas PG-SGA scale was done for all the cycles and dietary intervention was given to patients who were moderately and severely malnourished. Follow up was done for all the patients till the end of the therapy.
Results
Out of 97 patients 61% were females and 36% were males. During the chemotherapy third cycle 19.5% patients were found to be well nourished (stage A) 63% were moderately malnourished (stage B) and 17.5% were severely malnourished (stage C). After the chemotherapy sixth cycle 60% were in stage A and 34% were in stage B and 6% were in stage C. Qol was also assessed and the total score before and after the chemotherapy was found to be 54.2 + 11.46 and 46.16 + 9.77 respectively Whereas 23% of the patients showed higher score (9.8 + 3.6) in physical domain before the treatment and at the end of the treatment the score increased (22 + 4.1). Emotional domain before treatment (5.9 + 2.5) and after treatment (5.3 + 2.3) social (3.6 + 1.4 and 3.5 + 1.4) cognitive (2.04 + 0.31 and 2.04 + 0.30) and role (5.9 + 1.5 and 3.9 + 1.4).
Conclusions
Pre-emptive assessment of nutritional status and prompt dietary guidance and intervention can improve patient’s nutritional status and QOL.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Sri Prathima.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
313P - Immunotherapy application for advanced cancers: One institution experiences since 2016 to 2019
Presenter: Jo Pai Chen
Session: Poster display session
Resources:
Abstract
314P - An EGF motif of Del1 inhibits efficient angiogenesis and suppresses tumour growth in vivo
Presenter: Hisataka Kitano
Session: Poster display session
Resources:
Abstract
315P - Inhibition of JAK1 sensitizes human head and neck cancer cells to cetuximab
Presenter: James Bonner
Session: Poster display session
Resources:
Abstract
316TiP - Neoadjuvant and adjuvant pembrolizumab (pembro) plus standard of care (SOC) in patients (pts) with resectable locally advanced (LA) head and neck squamous cell carcinoma (HNSCC): The phase III KEYNOTE-689 study
Presenter: Ezra Cohen
Session: Poster display session
Resources:
Abstract
322P - Three-year overall survival update from the PACIFIC trial
Presenter: Yi-Long Wu
Session: Poster display session
Resources:
Abstract
323P - Novel tumour mutation score versus tumour mutation burden in predicting survival after immunotherapy in pan-cancer from MSK-IMPACT cohort
Presenter: Yuan Li
Session: Poster display session
Resources:
Abstract
324P - A novel anti-PD-1 antibody HLX10 study led to the initiation of combination immunotherapy
Presenter: Tsu Yi Chao
Session: Poster display session
Resources:
Abstract
325P - Association between immune-related adverse events and efficacy of immune checkpoint inhibitors in patients with advanced hepatocellular carcinoma
Presenter: Lawrence Wong
Session: Poster display session
Resources:
Abstract
326P - Autologous V gamma 9 V delta 2 T cell therapy to target Epstein Barr Virus (EBV)-related malignancies
Presenter: Esdy Rozali
Session: Poster display session
Resources:
Abstract
327P - Neoantigen profile of hepatocellular carcinoma reveals its correlation with tumour progression and clonal evolution
Presenter: Xiaolong Liu
Session: Poster display session
Resources:
Abstract